Bromocriptine-quick release (bromocriptine-QR), a sympatholytic dopamine D2 agonist, was evaluated in T2DM patients whose glycemia levels were not optimally controlled with glucagon-like peptide 1 receptor agonists [42]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.